CompletedPhase 2NCT00137800

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

Checked against the public recordLast updated Apr 3, 2020 · Source: ClinicalTrials.gov

StatusCompleted
PhasePhase 2
U.S. locations2
SponsorDana-Farber Cancer Institute
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Drug: OSI-774 (Tarceva)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Age: 70 years of age or older * Stage IV or IIIB non-small cell lung cancer (NSCLC) * Measurable tumor(s) * Three or more weeks since prior radiation therapy * Three or more weeks since prior major surgery * Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities. * Must be up and about more than 50% of waking hours. * Life expectancy of 8 weeks or more * Blood tests that show kidneys, liver and bone marrow to be working adequately * Completely healed from previous oncologic or other major surgery Exclusion Criteria: * Prior chemotherapy regimen for non-small cell lung cancer * Prior exposure to OSI-774 or similar treatments such as trastuzumab, ZD1839, C225, etc. * Uncontrolled central nervous system metastases * Concurrent active cancer * Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * Prior chemotherapy for any malignant disease * Difficulty swallowing * A disease or disorder that interferes with ability to digest and absorb food * A medical condition that could make it unsafe for patient to participate in this study

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Massachusetts General HospitalBoston, Massachusetts
  • Dana-Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 3, 2020. Always confirm current availability with the study team.

View original record ↗